Press Releases

and/or
583 News Releases found
Pictured: David R. Jones and Charles M. Rudin
Memorial Sloan Kettering Announces New Leadership in Thoracic Surgery and Oncology

Memorial Sloan Kettering Cancer Center has announced the appointment of David R. Jones as Chief of the Thoracic Service in the Department of Surgery, and Charles M. Rudin as Chief of the Thoracic Oncology Service, Division of Solid Tumor Oncology, in the Department of Medicine.
Pictured: Melissa L. Pilewskie
Media Advisory
MRI Right Before or After Surgery Does Not Benefit Women with Early Breast Cancer

A Memorial Sloan Kettering Cancer Center study shows that the use of MRI before or immediately after surgery in women with DCIS was not associated with reduced local recurrence or contralateral breast cancer rates.
Pressroom
Memorial Sloan Kettering Cancer Center Unveils New Pressroom and Broadcast Studio

Memorial Sloan Kettering Cancer Center today unveiled a new pressroom for journalists with enhanced features as well as the availability of an on-site broadcast studio.
Pictured: Robert Motzer
Media Advisory
New Preferred Standard of Care for Advanced Kidney Cancer Patients

Patients with advanced kidney cancer can now take advantage of a new treatment option that has far fewer troubling side effects – this, according to a large, international trial led by Memorial Sloan Kettering Cancer Center investigators.
Pictured: Micropapillary Morphology
Media Advisory
Study Suggests Pattern in Lung Cancer Pathology May Predict Cancer Recurrence after Surgery

A new study by thoracic surgeons and pathologists at Memorial Sloan Kettering Cancer Center shows that a specific pattern found in the tumor pathology of some lung cancer patients is a strong predictor of recurrence.
Media Advisory
Most Popular Ovarian Cancer Cell Lines Do Not Resemble Ovarian Cancer

Researchers from Memorial Sloan Kettering Cancer Center recently discovered that the most frequently used cancer cell lines in ovarian cancer research are not suitable models of ovarian cancer.
Jedd Wolchok
Combination of Drugs Produces Dramatic Tumor Responses in Advanced Melanoma Patients

The combination of the immunotherapy drug ipilimumab and the investigational antibody drug nivolumab led to long-lasting tumor shrinkage in more than half of patients with metastatic melanoma, according to results from a Phase I trial simultaneously published in The New England Journal of Medicine and presented at the 49th Annual Meeting of the American Society of Clinical Oncology.
Richard Carvajal
New Therapy Shown To Improve Progression-Free Survival and Shrink Tumors in Rare Cancer for the First Time

The experimental drug selumetinib is the first targeted therapy to demonstrate significant clinical benefit for patients with metastatic uveal melanoma, according to new Memorial Sloan Kettering Cancer Center research presented at the 49th annual meeting of the American Society of Clinical Oncology.
Ross Levine
Foundation Medicine and Memorial Sloan Kettering Cancer Center Announce Partnership to Advance Patient Care in Hematologic Cancers

Foundation Medicine and Memorial Sloan Kettering Cancer Center today announced a partnership that brings together clinical, genomic and computational expertise to advance patient care in hematologic cancers.
Large Genomic Study Identifies Endometrial Cancer Subtypes, Treatment Opportunities

Endometrial tumors can be reclassified into distinct subtypes based partly on their genomic makeup and may respond to targeted drugs already being tested in clinical trials, according to a large-scale genomic analysis led by researchers at Memorial Sloan Kettering Cancer Center and other centers within The Cancer Genome Atlas Research Network.